Attentional Bias in Body Dysmorphic Disorder (VAB)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sabine Wilhelm, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01398904
First received: July 15, 2011
Last updated: August 31, 2012
Last verified: August 2012

July 15, 2011
August 31, 2012
March 2011
Not Provided
Attention Pattern [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
Gaze tracking via an Eyelink II eye tracker will determine perception of visual information.
Same as current
Complete list of historical versions of study NCT01398904 on ClinicalTrials.gov Archive Site
  • Subjective Units of Distress Scale (SUDS) [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
    Participants will provide a distress score based on the facial images observed.
  • Facial Attractiveness [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
    Using a 9-point Likert scale, participants will rate the perceived most attractive and unattractive feature of their own and the control face.
Same as current
Not Provided
Not Provided
 
Attentional Bias in Body Dysmorphic Disorder
Attentional Bias in Body Dysmorphic Disorder

Body Dysmorphic Disorder (BDD) participants will demonstrate greater attentional biases as compared to healthy control (HC) participants. Greater attention bias will be associated with greater distress. Greater attention bias will be associated with greater symptom severity.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

The study will include 40 participants, consisting of 20 BDD participants and 20 matched healthy controls.

Body Dysmorphic Disorders
Not Provided
  • Body dysmorphic disorder (BDD) Participants
    Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
  • Healthy Controls
    Males and females 18 years of age or older with ability to provide informed consent and understand study staff.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
Not Provided
Not Provided

Inclusion Criteria for BDD and healthy control participants:

  • males and females 18 years of age or older
  • sufficient fluency of English to understand study staff, procedures, and questionnaires
  • ability to provide informed consent

Inclusion for BDD participants only;

  • primary diagnosis of Diagnostic and Statistical Manual 4th Edition (DSM-IV-TR) BDD
  • BDD Yale-Brown Obsessive Compulsive Disorder score (Y-BOCS) of > 20
  • primary facial/head concern

Exclusion Criteria:

  • Major medical or neurological conditions
  • schizophrenia, schizoaffective disorder, or any other current lifetime DSM-IV psychotic disorder that is not attributable to delusional BDD
  • current suicidality
  • current homicidality

Exclusion criteria for healthy controls:

  • Any current Axis I psychiatric illness
  • history of BDD
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01398904
2010P002912
No
Sabine Wilhelm, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Principal Investigator: Sabine Wilhelm, Ph. D. Massachusetts General Hospital
Study Director: Jennifer Greenberg, Psy. D. Massachusetts General Hospital
Massachusetts General Hospital
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP